The Effects on the Femoral Cortex of a 24 Month Treatment Compared to an 18 Month Treatment with Teriparatide: A Multi-Trial Retrospective Analysis
暂无分享,去创建一个
Andrew H. Gee | Graham M. Treece | Tristan Whitmarsh | Kenneth E. S. Poole | A. Gee | T. Whitmarsh | K. Poole | R. Dore | Robin Dore
[1] Andrew H Gee,et al. Mapping Bone Changes at the Proximal Femoral Cortex of Postmenopausal Women in Response to Alendronate and Teriparatide Alone, Combined or Sequentially , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] T. Keaveny,et al. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. , 2014, The Journal of bone and joint surgery. American volume.
[3] Andrew H Gee,et al. Predicting Hip Fracture Type With Cortical Bone Mapping (CBM) in the Osteoporotic Fractures in Men (MrOS) Study , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] Andrew H. Gee,et al. Imaging the femoral cortex: Thickness, density and mass from clinical CT , 2012, Medical Image Anal..
[5] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[6] G. Dalsky,et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. , 2005, Archives of internal medicine.
[7] S. Boonen,et al. Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] Gerard R. Ridgway,et al. Targeted Regeneration of Bone in the Osteoporotic Human Femur , 2011, PloS one.
[9] Andrew H Gee,et al. Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] T. Keaveny,et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] Andrew H. Gee,et al. High resolution cortical bone thickness measurement from clinical CT data , 2010, Medical Image Anal..
[12] E. Glass,et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. , 2009, The Journal of clinical endocrinology and metabolism.
[13] C. Graeff,et al. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: Results from the EUROFORS study , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] S. Boonen,et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. , 2008, The Journal of clinical endocrinology and metabolism.
[15] Andrew H. Gee,et al. Independent measurement of femoral cortical thickness and cortical bone density using clinical CT , 2015, Medical Image Anal..
[16] B. Ettinger,et al. Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] Hang Lee,et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.